Recent clinical trials targeting GPVI either directly with ACT017, Voors-Pette et al. (10) or indirectly with Revacept, Uphaus et al. (9) have shown great promise in reducing collagen-mediated platelet activation and improved stroke outcome without leading to bleeding complications (64). This evidence concerns the gene GP6 and stroke disorder.